Health · Hardware · Enterprise
Myris Therapeutics
Myris Therapeutics is a Pittsburgh-based precision oncology company building the next generation of antibody drug conjugates (ADCs). Formerly BioHybrid Solutions, Myris uses proprietary polymer chemistry rooted in Carnegie Mellon's ATRP (atom transfer radical polymerization) technology to grow polymer bottlebrushes on antibodies, achieving ultra-high drug-to-antibody ratios (DAR) of 50-300 - roughly 10 to 100 times higher than conventional ADCs. That capability opens up new chemical space for cancer payloads that were previously unusable, aiming to deliver more potent, precisely targeted therapies.